Literature DB >> 27556962

The pharmacokinetics of propofol in ICU patients undergoing long-term sedation.

Piotr Smuszkiewicz1, Paweł Wiczling2, Krzysztof Przybyłowski3, Agnieszka Borsuk4, Iwona Trojanowska1, Marta Paterska3, Jan Matysiak5, Zenon Kokot5, Edmund Grześkowiak3, Agnieszka Bienert3.   

Abstract

The aim of this study was to characterize the pharmacokinetics (PK) of propofol in ICU patients undergoing long-term sedation and to assess the influence of routinely collected covariates on the PK parameters. Propofol concentration-time profiles were collected from 29 patients. Non-linear mixed-effects modelling in NONMEM 7.2 was used to analyse the observed data. The propofol pharmacokinetics was best described with a three-compartment disposition model. Non-parametric bootstrap and a visual predictive check were used to evaluate the adequacy of the developed model to describe the observations. The typical value of the propofol clearance (1.46 l/min) approximated the hepatic blood flow. The volume of distribution at steady state was high and was equal to 955.1 l, which is consistent with other studies involving propofol in ICU patients. There was no statistically significant covariate relationship between PK parameters and opioid type, SOFA score on the day of admission, APACHE II, predicted death rate, reason for ICU admission (sepsis, trauma or surgery), gender, body weight, age, infusion duration and C-reactive protein concentration. The population PK model was developed successfully to describe the time-course of propofol concentration in ICU patients undergoing prolonged sedation. Despite a very heterogeneous group of patients, consistent PK profiles were observed.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  long-term sedation; mechanical ventilation; pharmacokinetics; propofol

Mesh:

Substances:

Year:  2016        PMID: 27556962     DOI: 10.1002/bdd.2028

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  2 in total

1.  The use of PBPK modeling across the pediatric age range using propofol as a case.

Authors:  Robin Michelet; Jan Van Bocxlaer; Karel Allegaert; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-08       Impact factor: 2.745

2.  Propofol use in newborns and children: is it safe? A systematic review.

Authors:  Eduardo Mekitarian Filho; Mariana Barbosa Riechelmann
Journal:  J Pediatr (Rio J)       Date:  2020-01-08       Impact factor: 2.990

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.